Health Condition 1: I10- Essential (primary) hypertension
Conditions
Interventions
Intervention1: pharmacotherapy: pharmacotherapy for anxiety ( Tab escitalopram ) + pharmacotherapy for hypertension for a total duration of 12 weeks
Control Intervention1: pharmacotherapy: pharmacothe
Sponsors
All india institue of medical sciences, New Delhi
Eligibility
Inclusion criteria
Inclusion criteria: Inclusion criteria: 1. Hypertensive patients on at least 2 anti hypertensives. 2. Diagnosed with generalized anxiety disorder according to the DSM-5 criteria 3.Patient in the mild to moderate category of GAD (HAM A less than 25)
Exclusion criteria
Exclusion criteria: Exclusion criteria: 1. Patients with functional disability due ot anxiety. 2. Long QTc on Baseline ECG, or concomitant QTc prolonging drugs. 3. Patients with a primary psychiatric diagnosis other than anxiety disorder will be excluded, including patients with MDD (major depressive diorder), PTSD (post traumatic stress disorder), OCD (obsessive compulsive disorder), or any of the following DSM-5 diagnoses: 1) Dementia, delirium; 2) Schizophrenia, Schizoaffective, or other psychotic disorder; 3) Psychotic features including any delusions or hallucinations. 4. Patients with secondary causes of hypertension. 5. Current alcohol or other substance abuse disorder. 6. Patient taking herbal supplements. 7. Pregnant and lactating females will be excluded.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Change in anxiety symptoms as assessed by Hamilton Anxiety Rating scale (HAM-A).Timepoint: 4 weeks, 12 weeks | — |
Secondary
| Measure | Time frame |
|---|---|
| Change in blood pressure controlTimepoint: 4 weeks, 12 weeks;adverse eventsTimepoint: 4 weeks, 12 weeks;change in quality of life assessed by WHOQOL-BREF questionnaireTimepoint: 4 weeks, 12 weeks | — |
Countries
India
Contacts
Public ContactDaksh Bansal
AIIMS New Delhi
Outcome results
None listed